GTC Biotherapeutics (fka GTCB)

[read_this_n0w]

re INSM deal: Keep in mind insmed had a complex biologic of its own and subsequent highly advance purificiation train.
Plus their lead drug iplex igf1-igf1bp3 was unsuccesfully attempted to produce by giants suchs as Genentech.. whom failed.

as a result that purification could be combined with standard production methods in creating very good comparable biogenerics with high levels of purity

Gtcb on the other hand is likely to have variations in the produced compound due to the trangenic production method and this adds risk to any biogeneric aim. Ie less (a damn lot less) likely to see investment at this stage into that .